CN102228576A - Chinese patent medicine for treating discoid lupus erythematosus - Google Patents
Chinese patent medicine for treating discoid lupus erythematosus Download PDFInfo
- Publication number
- CN102228576A CN102228576A CN2011101565231A CN201110156523A CN102228576A CN 102228576 A CN102228576 A CN 102228576A CN 2011101565231 A CN2011101565231 A CN 2011101565231A CN 201110156523 A CN201110156523 A CN 201110156523A CN 102228576 A CN102228576 A CN 102228576A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese patent
- patent medicine
- lupus erythematosus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 title claims abstract description 25
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 title claims abstract description 25
- 241000555682 Forsythia x intermedia Species 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 11
- 241000405217 Viola <butterfly> Species 0.000 claims description 7
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- -1 sublimed preparation Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 8
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 208000017520 skin disease Diseases 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 2
- 241000282817 Bovidae Species 0.000 abstract 1
- 241001050741 Dipsacus asperoides Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 240000002045 Guettarda speciosa Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 244000207740 Lemna minor Species 0.000 abstract 1
- 235000006439 Lemna minor Nutrition 0.000 abstract 1
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241001530126 Scrophularia Species 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 241000246044 Sophora flavescens Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 240000006688 Telosma cordata Species 0.000 abstract 1
- 235000017352 Telosma cordata Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 230000009323 psychological health Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 206010015150 Erythema Diseases 0.000 description 27
- 231100000321 erythema Toxicity 0.000 description 27
- 208000002193 Pain Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 210000000214 mouth Anatomy 0.000 description 20
- 206010025135 lupus erythematosus Diseases 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 16
- 230000006870 function Effects 0.000 description 14
- 208000006820 Arthralgia Diseases 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 230000001047 pyretic effect Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 7
- 241000555712 Forsythia Species 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 206010040882 skin lesion Diseases 0.000 description 7
- 231100000444 skin lesion Toxicity 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 201000000736 Amenorrhea Diseases 0.000 description 6
- 206010001928 Amenorrhoea Diseases 0.000 description 6
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 6
- 231100000540 amenorrhea Toxicity 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 208000015220 Febrile disease Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 201000000297 Erysipelas Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010043458 Thirst Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000002497 edematous effect Effects 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 208000008494 pericarditis Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010015218 Erythema multiforme Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 238000003723 Smelting Methods 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000036561 sun exposure Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 210000000216 zygoma Anatomy 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010016741 Fixed eruption Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000006802 Lupus erythematosus panniculitis Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 201000006994 chronic ulcer of skin Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Abstract
The invention discloses a Chinese patent medicine for treating discoid lupus erythematosus, which belongs to the technical field of treatment of skin diseases. The Chinese patent medicine is prepared from the following Chinese medicinal herbs in parts by weight: 10-20 parts of rehmanniae praeparatum, 15-25 parts of red paeony root, 15-25 parts of achyranthis bidentatae, 20-30 parts of dandelion, 20-30 parts of Chinese violet, 30-40 parts of red-rooted salvia, 15-25 parts of pollen, 15-25 parts of angelica, 15-25 parts of white paeony root, 15-25 parts of fructus forsythia, 15-25 parts of scutellaria, 10-15 parts of liquorice, 8-12 parts of dipsacus asperoides, 9-16 parts of scrophularia, 15-25 parts of cortex lycii radicis, 15-25 parts of Sophora flavescens, 10-20 parts of antelope horn, 10-20 parts of duckweed and 10-20 parts of rhizoma alismatis. Compared with the prior art, the Chinese patent medicine for treating the discoid lupus erythematosus has outstanding substantial characteristics and obvious advantages of removal of the diseases of patients, promotion of physical and psychological health, convenience for taking, quick therapeutic effect and no side effect.
Description
Technical field:
Invention relates to the treatment technology field of dermatosis, relates in particular to a kind of Chinese patent drug technique field that is used for the treatment of discoid lupus erythematosus.
Background technology
The plate-like lupus erythematosus is a kind of of lupus erythematosus.The main skin of invading is type the lightest in the lupus erythematosus.Minority can have slight visceral lesion.Skin lesion just time-out is a slice or several pieces scarlet mottles, and Semen phaseoli radiati is big to Semen Glycines, and there is adhesive scale on the surface, enlarge gradually later on, and rounded or irregular shape, the edge pigment is obviously deepened, a little more than the center.Central authorities' color is light, but atrophy, low-lying, and whole skin lesion is plate-like (so name discoid lupus erythematosus).Infringement mainly is distributed in the sun exposure position, and as face, helix and scalp, minority can be involved breast, the back of the hand, forearm, lip and oral mucosa and also can be got involved.Most of patients skin lesion no conscious sympton, but be difficult to disappear fully.New infringement can increase gradually or be constant for many years, and infringement is evacuated and is symmetrically distributed, and also can merge mutually in flakes, and the infringement at face middle part can be fused into butterfly.The plate-like skin lesion is in sunlight exposure or tired postemphasis.Infringement on the scalp can cause permanent alopecia.The old infringement can develop into cutaneous squamous cell carcinoma occasionally.
According to pathogenic factor, the pathological change of discoid lupus erythematosus, learn through multi-party verification, cause the reason of discoid lupus erythematosus to mainly contain following several:
1, inherited genetic factors.Heredity is the key factor of lupus erythematosus morbidity, has the people of lupus erythematosus inherited genetic factors, in case run into the condition of bringing out in some environment, will cause this disease.Black people Aisan suffers from lupus erythematosus and is higher than white man according to investigations, and the incidence rate height of lupus erythematosus family history is arranged, and sickness rate is higher among the one.
2, infective agent.In SLE patient's glomerule endotheliocyte and skin lesion, find inclusion body and class inclusion body material, antiviral antibody increases in the serum, separablely in the SLE animal model NZB/NZW mouse tissue go out C type virus (slow virus), and in glomerule, can record the antibody of C type VAA.
3, the endocrine factors lupus erythematosus is mainly in the women of child-bearing age, asexuality difference almost in child and gerontal patient.Lupus erythematosus often takes place in male's hypoplasia of testis patient, and no matter the men and women all has the estrone hydroxylation product to increase in the lupus erythematosus patient.
4, environmental factors.Environmental factors is the factor of directly bringing out lupus erythematosus, comprises physics aspect and chemical aspect.Physical factor such as ultraviolet radiation, chemical factor such as medicine have some medicines can cause drug induced lupus and increase the weight of lupus erythematosus.
5, other factors.In daily life, as improper diet, eaten shrimp, Eriocheir sinensis, Folium Allii tuberosi, Herba Apii graveolentis, mushroom, Fructus Fici and some soybean pod class plants etc., lived in newly-decorated house, hair dyeing etc. can be brought out erythema.
And the medicine for the treatment of discoid lupus erythematosus at present has Chinese medicine, Western medicine, but curative effect does not all make patient satisfaction; And some drug toxicity is bigger, and therapeutic process injures health, has brought many miseries to the patient.
Summary of the invention:
Technical problem to be solved by this invention provides a kind of to eliminate patient's illness, promotion physical and mental health, the Chinese patent medicine that has the treatment discoid lupus erythematosus that the patient takes medicine conveniently, curative effect is fast, have no side effect simultaneously.
For solving the problems of the technologies described above, the present invention adopts following technical scheme: a kind of Chinese patent medicine for the treatment of discoid lupus erythematosus, and its special character is to be prepared from by following medicaments in part by weight: Radix Rehmanniae 20-30 part, Radix Paeoniae Rubra 15-25 part, Cortex Moutan 15-25 part, Radix Achyranthis Bidentatae 15-25 part, Herba Taraxaci 20-30 part, Herba Violae 20-30 part, Radix Salviae Miltiorrhizae 30-40 part, pollen 15-25 part, Radix Angelicae Sinensis 15-25 part, Radix Paeoniae Alba 15-25 part, Fructus Forsythiae 15-25 part, Radix Scutellariae 15-25 part, Radix Glycyrrhizae 10-15 part, Radix Dipsaci 8-12 part, Radix Scrophulariae 9-16 part, Cortex Lycii 10-15 part, Radix Sophorae Flavescentis 10-15 part, Cornu Saigae Tataricae 10-20 part, Herba Spirodelae 10-20 part, Rhizoma Alismatis 10-20 part.
The preferred version of said medicine weight portion is: Radix Rehmanniae 22-28 part, Radix Paeoniae Rubra 18-22 part, Cortex Moutan 18-22 part, Radix Achyranthis Bidentatae 18-22 part, Herba Taraxaci 22-28 part, Herba Violae 22-28 part, Radix Salviae Miltiorrhizae 32-38 part, pollen 18-22 part, Radix Angelicae Sinensis 18-22 part, Radix Paeoniae Alba 18-22 part, Fructus Forsythiae 18-22 part, Radix Scutellariae 18-22 part, Radix Glycyrrhizae 11-14 part, Radix Dipsaci 9-11 part, Radix Scrophulariae 10-15 part, Cortex Lycii 11-14 part, Radix Sophorae Flavescentis 11-14 part, Cornu Saigae Tataricae 12-18 part, Herba Spirodelae 12-18 part, Rhizoma Alismatis 12-18 part.
The preferred plan of said medicine weight portion is: 25 parts in the Radix Rehmanniae, 20 parts of Radix Paeoniae Rubra, 20 parts of Cortex Moutans, 20 parts of Radix Achyranthis Bidentataes, 25 parts of Herba Taraxacis, 25 parts of Herba Violaes, 35 parts of Radix Salviae Miltiorrhizaes, 20 parts of pollen, 20 parts of Radix Angelicae Sinensis, 20 parts of the Radix Paeoniae Albas, 20 parts of Fructus Forsythiaes, 20 parts of Radix Scutellariae, 12 parts in Radix Glycyrrhizae, 10 parts of Radix Dipsaci, 12 parts of Radix Scrophulariae, 12 parts of Cortex Lycii, 12 parts of Radix Sophorae Flavescentiss, 15 parts of Cornu Saigae Tataricae, 15 parts in Herba Spirodelae, 15 parts of Rhizoma Alismatis.
Above-mentioned described Chinese patent medicine is made pill, sublimed preparation, powder, tablet, unguentum, decoction and the different oral medicine dosage form of capsule dress powder according to the conventional technology of preparing of Chinese medicine.Above-mentioned described Chinese patent medicine also contains drug excipient.
The principles of formulating prescriptions of Chinese patent medicine of the present invention are: to regulate the blood flow circulation, painful antipruritic, the cooling blood and dissolving purpura in clearing away heart-fire, expelling wind and removing dampness, kidney tonifying detoxifcation, town, enhancement telangiectasis, improve immune function of human body, thereby reach the purpose of treatment plate-like erythema disease.The present invention has proper, the reasonable recipe of compatibility of drugs, and the effect of its described each herbal medicine is:
The Radix Rehmanniae: another name: Radix Rehmanniae, marrow, smart, the benzyl root of sun, be goatweed.The property flat, bitter in the mouth, be used as medicine with ratan on the Chinese medicine, function heat-clearing and toxic substances removing, promoting blood circulation to restore menstrual flow cure mainly diseases such as arthralgia.
Radix Paeoniae Rubra: sour in the mouth, hardship, cool in nature.Go into liver, spleen channel.Effect: clots absorbing, pain relieving, removing heat from blood, detumescence.Cure mainly: control the stagnant amenorrhea of the stasis of blood, the hernia abdominal mass is gathered, stomachache, hypochondriac pain, epistaxis, dysentery, discharging fresh blood stool, conjunctival congestion, carbuncle.
Cortex Moutan: bitter in the mouth, cool in nature, be slightly cold.GUIXIN, liver, kidney, lung meridian.Effect cures mainly: clearing away heat and cooling blood; Promoting blood circulation to remove blood stasis.The epidemic febrile disease pathogenic heat attacking blood system in febrile diseases; Send out speckle; Tell nosebleed; The calentura later stage, hot Fu Yin divided heating; Deficiency of YIN osteopyrexia and fever; Amenorrhea due to stagnation of blood; Dysmenorrhea; Carbuncle sore tumefacting virus; Fall and pounce on the pain of injury; The rheumatism pyretic arthralgia.
Radix Achyranthis Bidentatae: bitter in the mouth, acid, property is flat.Return liver, kidney channel.Function cures mainly: invigorating the liver and kidney, bone and muscle strengthening, eliminating blood stasis and inducing menstruation, conducting blood to flow downwards.Be used for soreness of waist and knee joint, muscles and bones is unable, amenorrhea lump in the abdomen, dizziness due to hyperactivity of liver-YANG.
Herba Taraxaci: bitter in the mouth, sweet, cold in nature.Function cures mainly: heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, inducing diuresis for treating stranguria syndrome.Be used for furuncle swelling toxin, acute mastitis, scrofula, conjunctival congestion, pharyngalgia, lung abscess, acute appendicitis, jaundice due to damp-heat, the puckery pain of pyretic stranguria.
Herba Violae: bitter in the mouth, suffering, cold.GUIXIN, lung meridian.Function with cure mainly: heat-clearing and toxic substances removing.Be used for furuncle, carbuncle, erysipelas, scrofula, jaundice, dysentery, diarrhoea, conjunctival congestion and swelling pain, sore throat, mumps, venom.
Radix Angelicae Sinensis: sweet in the mouth, suffering, warm in nature.Return liver, the heart, spleen channel.Function with cure mainly: enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.Be used for blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.
The Radix Paeoniae Alba: bitter in the mouth, acid, cold nature.Main smelting: menoxenia, abdominal pain during menstruation, metrorrhagia, spontaneous perspiration, night sweat, side of body rib epigastric pain, limb pain twin, headache, dizzy.
Fructus Forsythiae: bitter in the mouth, cold nature.Return Liver Channel.Function: heat-clearing and toxic substances removing, mass dissipating and swelling eliminating.Cure mainly: Chinese medicine is controlled calentura from the beginning of, anemopyretic cold, and heating is vexed, laryngopharynx swelling and pain, macule, erysipelas, scrofula, carbuncle pyogenic infections from tumour or sore, acute nephritis, pyretic stranguria.
Radix Scutellariae: bitter in the mouth, cold in nature.Return lung, gallbladder, spleen, large intestine, small intestine meridian.Function cures mainly: heat clearing and damp drying, and eliminating fire and detoxication, hemostasis, antiabortive.Be used for hygropyrexia, fever disease in summer vomiting and nausea uncomfortable in chest, damp and hot feeling of fullness, dysentery, jaundice, the cough due to lung-heat, the hyperpyrexia excessive thirst, heat in blood is told nosebleed, carbuncle sore tumefacting virus, frequent fetal movement.
Radix Salviae Miltiorrhizae: bitter in the mouth, little suffering, cold nature; Go into the heart, spleen, liver, kidney footpath; Effect: have blood circulation promoting and blood stasis dispelling, nourishing blood to tranquillize the mind, removing heat from blood repercussive effect; Cure mainly: blood stasis head, breast, the side of body, abdomen pain, gather, menoxenia, the dysmenorrhea amenorrhea, the stasis of blood stagnated and suffered from abdominal pain puerperal, arthralgia, the traumatic injury congestive edema, epidemic febrile disease is vexed, palpitation due to deficiency of blood, sore swollen toxin, red rash scabies.
Pollen: pollen originates from the flower of each kind of plant, so the kind of pollen has a lot, effect also all has nothing in common with each other, but general pollen all has the effect of some source plants.But no matter be the pollen of what flower, it all is a kind of good health product, and nutritious scholar says that pollen is the most comprehensive a kind of dietetic therapy good merchantable brand, can beautifying and anti-aging, can health invigorating, and strengthen spirit, can also eliminate physical fatigue fast.It both can also can take orally in external, was the good merchantable brand of building body looks improving and the skin nourishing.
Radix Glycyrrhizae: sweet in the mouth, property is flat; Return 12 warps.Effect: detoxifcation is arranged, eliminate the phlegm, pain relieving, spasmolytic be so that pharmacological action such as anticancer.On the traditional Chinese medical science, the Radix Glycyrrhizae invigorating the spleen and replenishing QI is grown and to be coughed lung moistening, and the emergency detoxifcation is in harmonious proportion hundred medicines.The clinical practice branch " is given birth to and uses " with " processed with honey " not.Give birth to curing mainly laryngopharynx swelling and pain cellulitis skin infection, gastrointestinal ulceration and separate poison of drug, alimentary toxicosis etc.; Processed with honey cures mainly spleen and stomach function and goes down, and big loose stool is thin, weak heating and cough, cardiopalmus etc.
Radix Sophorae Flavescentis: bitter in the mouth; Liver, kidney, large intestine, small intestinal, bladder, heart channel of returning cold in nature.Function cures mainly: heat clearing and damp drying, wind dispelling insecticide.Damp-heat dysentery, discharging fresh blood stool, jaundice, dysuria, edema, leukorrhagia, pudendal pruritus, scabies, leprosy, skin pruritus, noxious dampness skin infection.
Cornu Saigae Tataricae: salty in the mouth, cold in nature.Function: clearing away heat and relieving spasm, suppressing the hyperactive liver to relieve the wind syndrome, removing toxic substances and promoting subsidence of swelling.(relieving spasm by subduing liver-wind liver heat removing and eyesight improving heat-clearing and toxic substances removing) cures mainly: unconsciousness due to high fever, delirium are gone mad, diseases such as infantile convulsion is twitched, conjunctival congestion and swelling pain.The Radix Paeoniae Alba: bitter in the mouth, acid, cold nature.Main smelting: menoxenia, abdominal pain during menstruation, metrorrhagia, spontaneous perspiration, night sweat, side of body rib epigastric pain, limb pain twin, headache, dizzy.
Cortex Lycii: nature and flavor are cold in nature, sweet in the mouth.Function cures mainly: removing heat from blood removes and steams the lung heat clearing pathogenic fire reducing.Be used for deficiency of YIN hectic fever, hectic fever due to YIN-deficiency night sweat, cough due to lung-heat, spitting of blood, epistaxis.
Radix Scrophulariae: sweet, salty, little hardship, cold.Go into lung, stomach, kidney channel.Effect is used: removing heat from blood YIN nourishing, eliminating fire and detoxication, fever excessive thirst, spontaneous sweating, constipation, haematemesis nose bleeding, pharyngolaryngitis, pulmonary tuberculosis.Be used for consumption of YIN caused by febrile disease, crimson tongue excessive thirst, maculae caused by violent heat pathogen, Tianjin and hinder constipation, hectic fever due to YIN-deficiency chronic cough, conjunctival congestion, pharyngalgia, scrofula, diphtheria, carbuncle sore tumefacting virus.
Plumula Nelumbinis: bitter in the mouth, cold in nature.Be included into the heart, lung, kidney three warps.Function: clear away heart-fire, reduce phlegm and internal heat, hemostasis, arresting seminal emission.Control vexedly, thirsty, spit blood seminal emission, conjunctival congestion and swelling pain.
Herba Spirodelae: acrid in the mouth, cold in nature.Nontoxic.Go into lung, liver, spleen channel.Effect: diaphoresis, dispel the wind row water, heat clearing away, detoxifcation.Cure mainly: the hot carbuncle of row when controlling, macule is not saturating, wind heat pain rash, skin pruritus, edema, amenorrhea, the skin ulcer tinea, erysipelas is scalded.
Rhizoma Alismatis: sweet in the mouth is light; Cold in nature.Return kidney; Urinary bladder channel.Function cures mainly: promoting diuresis to eliminate damp pathogen; It is treating stranguria to expel the heat-evil.Cure mainly dysuria; The puckery pain of pyretic stranguria; The edema distension; Have loose bowels; Dizziness due to fluid-retention; Seminal emission.
The Chinese medicine and pharmacy theory is thought: in scorchingly hot vehement be lupus erythematosus main diseases because of, the patient of primary disease 90% is with heating, this is the gesture of pathogenic heat aggressiveness.Scorchingly hot pluging with molten metal tied in nutrient blood, thus outer show speckle, in heating is arranged, very the person is evil covers clear key, dusk is raved tic, so the traditional Chinese medical science has " maculae caused by violent heat pathogen ", titles such as " pyretic toxicity are sent out speckle ".Clinical is many with scorchingly hot flourishing type also in acute stage.Study carefully its scorchingly hot origin, have diseases caused by exogenous pathogenic factor and interior life not.The diseases caused by exogenous pathogenic factor pyretic toxicity mostly with to tan by the sun daylight relevant, also has because of experiencing rheumatism, accumulates the resistance skin, stays and does not go, and then turns to pyretic toxicity for a long time.In makes pyretic toxicity and often can not make fire by the deficiency of YIN so that give birth in the pathogenic fire, so lose cloudy Tianjin day, YANG toxin syndrome day contains, the formation vicious cycle.
The present invention follows the principles of formulating prescriptions of the traditional Chinese medical science " monarch ", all composition comes from the 5th edition medicine that records of China's " pharmacopeia ", all medicines have temperature compensation liver spleen mutually and altogether, the wind dehumidifying of loosing, QI and blood regulating, dredge the meridian passage, blood circulation promoting and blood stasis dispelling, set upright and get rid of evils, regulate immunologic function, improve skin microcirculation, reach treatment and prevention discoid lupus erythematosus disease, determined curative effect, have no side effect various Chinese medicine preparation taking conveniences.
The clinical use result of Chinese patent medicine of the present invention shows to have following advantage:
1, the Chinese medicine each component selected for use of the present invention meets the regulation of The Drug Administration Law of People's Republic of China, utilizes the comprehensive function treatment and the prevention discoid lupus erythematosus disease of the Chinese medicine of respectively distinguishing the flavor of, and is nontoxic to human body.Acute toxicity test and accumulation toxicity test through white mice and rat show that underproof animal does not see any toxic reaction, compare zero difference through anatomic observation hemogram, liver function, each organs and tissues morphology finding and matched group, prove that its safety of medicine is reliable.
2, Chinese patent medicine preparation of the present invention need not decoct, not have bitterness sense, rich in proteins, glucose, glucuronic acid, volatile oil, pectin, fructose, organic acid, lecithin, vitamin, aminoacid in the medicine, also contain various trace elements such as Saponin, plant sterol, calcium, help absorption of human body, health invigorating, and taking convenience.
3, Chinese patent medicine preparation of the present invention not only can effectively be treated the discoid lupus erythematosus disease, and it is also very obvious to the preventive effect of discoid lupus erythematosus disease, particularly by working in coordination with mutually between the medicine, strengthen medicine and treat characteristic separately, by dredge the meridian passage and adjusting immunologic function, improve the intrinsic healthy energy of patient body and physical and mental health and life quality, reached the healing rehabilitation efficacy preferably.
Further specify the effect of Chinese patent medicine of the present invention below by clinical practice to the treatment discoid lupus erythematosus.
One. the clinical diagnosis standard
Because primary disease etiology unknown, clinical manifestation are changeful, the tissue and the organ that involve are more, state of an illness complexity, and the patient or one, two internal organs affected individual is only arranged of particularly not being true to type in early days, or do not have erythra, even do not have clinical manifestation.What now adopt be American Rheumatism Association (ARA) diagnostic criteria through correction in nineteen eighty-two, totally 11: 1. cheekbone cheek erythema; 2. discoid lupus; 3. photaesthesia; 4. oral ulcer; 5. not aggressive arthritis; 6. albuminuria (＞0.5g/d) or urine thin born of the same parents cast; 7. epilepsy or psychosis; 8. pleuritis or pericarditis; 9. hemolytic anemia or leukopenia (＜4000/mm3) or lymphopenia (＜1500/mm3) or thrombocytopenia (＜100000/mm3); 10. anti-ds-DNA antibody or anti-Sm antibody or LE cell or syphilis seroreaction false positive.Meeting above the beginning more than four or four can make a definite diagnosis, and the sensitivity of this diagnostic criteria and specificity all can reach 96%, if in conjunction with lupus band test and biopsy, and more can high diagnosis.And the clinical diagnosis standard of discoid lupus erythematosus is:
1. butterfly erythema or plate-like erythema: spread all over the flat of cervical region or exceed the skin fixed eruptions, often do not involve the nasolabial fold position, the plate-like erythema is covered with cutin squama and hair follicle damage on the protuberance erythema, can cause atrophoderma.
2. photaesthesia: sun exposure causes skin allergy.
3. stomatocace: oral cavity or nasopharynx part callous ulcer.
4. non-arthritis deformans or Polyarthralgia: be characterized as swollen, the pain or the sepage in joint.
5. pleuritis or pericarditis: chest pain, pleura crunch or pleural effusion, pericarditis.
6. epilepsy or mental symptom: as uremia, ketoacidosis or electrolyte disturbance cause psychosis:
7. albuminuria, cylinderuria or hematuria: albuminuria＞0.5g/dl or 3+; Cellular cast can be erythrocyte, hemoglobin, granular cast or mixes cast.
8. the puzzled less hemolytic anemia of leukocyte.
9. the FANA positive.
10. the anti-dsDNA antibody positive or the lupus cell positive.
11. the anti-Sm antibody positive.
12. lupus band test (the non-skin lesion position) positive or the kidney biopsy positive.
Meet in above-mentioned any 4 and diagnosablely be discoid lupus erythematosus.
Check foundation:
1, blood routine examination.
2, X ray examination.
The immunologic dysfunction of lupus erythematosus can produce many kinds of materials in the body, make organism fever as pyrogen.About 80% patient can have heating, and great majority are hyperpyrexia, and about 12% patient shows as low grade fever.First symptom of some patient is exactly the heating of unknown cause.
The patient of erythema erythra more than 80% has skin lesion, and erythema, erythra present various type.Facial butterfly-like erythema of cheekbone and first week, the finger tip edematous erythema is existing for lupus erythematosus feature performance mark sheet.
Butterfly erythema is no more than nasolabial fold, and the bridge of the nose, volume, auricle also can have irregular shape erythema.Also difform erythema can be arranged at positions such as the last elbow back of the body, the palm back of the body, dactylus, the apotelus back side, palm, vola portions.Shape has plate-like erythema, erythema iris, edematous erythema, erythema multiforme etc.Mucosal ulcer and alopecia have 1/5 patient that mucosal injury is arranged approximately, involve lip, tongue, cheek, nose, chamber etc., painless property mucosal ulcer occurs.If any secondary infection pain can be arranged.
Arthralgia has the patient more than 90% that arthralgia is arranged, and each stadium all may take place.What arthralgia had occurred in the premorbid several years, and the periarticular soft tissues swelling that has is touched a tender spot and hydrops, was the acute arthritis performance.That gets involved that the position sees more has near-end articulations digitorum manus, metacarpophalangeal joints, wrist, elbow, knee joint, an apotelus etc., and symmetry is often arranged.Part patient has the deadlock in morning.Some patient joint course of disease is longer, also has patient to have only in short-term and occurs, even be the property a crossed arthralgia.
Two. case selection
The sickness rate of lupus erythematosus profundus is with area, the ethnic group colour of skin and different, prevalence is less in the population of China, put down in writing according to interrelated data: age of onset is in the majority in year at 20-50, account for 80% of sum, for this reason, case selection is whole cases totally 16 examples with door rash prescription on individual diagnosis patient, diagnoses according to " clinical diagnosis standard ": limitation discoid lupus erythematosus disease patient 14 examples, system's discoid lupus erythematosus disease 2 examples.
Three. curative effect determinate standard
1. clinical remission (in the recent period control): symptom and sign disappears, and lab testing recovers normally substantially, energy operate as normal and activity.
2. produce effects: symptom and sign disappears or significantly improves, and lab testing significantly improves or recovers normal, can participate in light work, the recovery general activity.
3. take a turn for the better: symptom and sign and lab testing make moderate progress.
4. invalid: clinical and lab testing improves not obvious or deterioration, death.
Four, clinical application method and therapeutic outcome
1, clinical application method
In that the patient is observed on the basis of condition of illness sign and laboratory examination, make a definite diagnosis.After being diagnosed as discoid lupus erythematosus, adopt the Chinese patent medicine of the oral embodiment of the invention usually, reach replenishing YIN and blood, wind-dispelling heat-dissipating, eliminating dampness and dredging channels; Clearing away heat-damp and promoting diuresis, promoting blood circulation to remove obstruction in the collateral; Removing pathogenic heat from blood and toxic substance from the body, disperse blood stasis and dredge collateral.Also can adopt the oral administration and externally used Therapeutic Method that combines for particular patients '.Wherein:
For oral administration: take the pill of embodiment 5, each 5-9 gram, every day 3-4 time, warm water delivery service, take half an hour ante cibum.Two months is a course of treatment, take continuously three the course of treatment observe the curative effect.
External: with the medicine of embodiment, put into container and be heated to boiling 30 minutes, insulation then, it is stifling or embathe affected part that affected part is put container top, once a day, each 30 minutes.Or the medication water logging washes affected part,
2. clinical therapeutic efficacy
The inventor accepts discoid lupus erythematosus patient 16 examples from 2007-2010 for medical treatment in 4 years altogether, male's 6 examples, and women's 10 examples, the age is 16-55 year.Clinical remission 3 examples account for 18.7% among the 16 routine patients, and produce effects 6 examples account for 37.5%, and effective 5 examples account for 31.3%, and invalid 2 examples account for 12.5%, and total effective rate reaches 87.5%.Clinical symptoms obviously alleviates, big recovery of function, and patient do not have any untoward reaction, three big routine tests and hepatic and renal function and internal organs infringement symptom detect do not find any unusual.Fully recover through the patient and to pay a return visit statistics, do not see an example recurrence so far.Typical case's introduction of falling ill:
1, Chen Changhai, the man, 49 years old, live the Laishan District, Yantai City, the cadre of bank, back and skin of lumbar region carry on the back, slap positions such as the back of the body, dactylus, the apotelus back side, palm, vola portion at last elbow have difform erythema.Shape erythema iris, edematous erythema, erythema multiforme etc.Repeatedly utilize folk prescription or go to see a doctor, all to no effect, use this pharmaceutical formulation (for oral administration, external) after course of treatment, skin skin bud treasure, erythema, pain, podomere are ached and are alleviated, after three courses of treatment, back and skin of lumbar region erythema, pain, heating, the podomere transference cure of aching, after nine courses of treatment, it is normal that pars affecta skin recovers.
2, Feng Shaojun, the man, 32 years old, live Chi Shan town, flourish city, the teacher, the skin bridge of the nose, forehead, auricle also can have irregular shape erythema.Shape has erythema iris and is mixed with arthralgia etc.Repeatedly go to see a doctor, all do not have remarkable result, use this pharmaceutical formulation (for oral administration, external) after the course of treatment, skin nodules, scorching hot pain, heating alleviate, after three courses of treatment, and erythema, scorching hot pain, heating, thirsty agitation, arthralgia disappear, and after nine courses of treatment, it is normal that pars affecta skin recovers.
3, Yu Aijuan, the woman, 40 years old, live the Wang Zhuanzhen of Wendeng City, the worker, the bridge of the nose, volume, auricle also can have irregular shape erythema.Shape has erythema iris and is mixed with arthralgia etc.Multi-treatment does not all have positive effect, makes troubles to family life, causes patient's stress and limbs misery.After the course of treatment, red swelling of the skin, brothers' heating paresthesia alleviate to use this pharmaceutical formulation (for oral administration, external), and after three courses of treatment, above-mentioned symptom disappears, and after nine courses of treatment, it is normal that pars affecta skin recovers.
The specific embodiment
Embodiment 1
Press the row weight portion and take by weighing each Chinese crude drug: 20 parts in the Radix Rehmanniae, 15 parts of Radix Paeoniae Rubra, 15 parts of Cortex Moutans, 15 parts of Radix Achyranthis Bidentataes, 20 parts of Herba Taraxacis, 20 parts of Herba Violaes, 30 parts of Radix Salviae Miltiorrhizaes, 15 parts of pollen, 15 parts of Radix Angelicae Sinensis, 15 parts of the Radix Paeoniae Albas, 15 parts of Fructus Forsythiaes, 15 parts of Radix Scutellariae, 10 parts in Radix Glycyrrhizae, 8 parts of Radix Dipsaci, 9 parts of Radix Scrophulariae, 10 parts of Cortex Lycii, 10 parts of Radix Sophorae Flavescentiss, 10 parts of Cornu Saigae Tataricae, 10 parts in Herba Spirodelae, 10 parts of Rhizoma Alismatis.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made sublimed preparation according to the pharmaceutical methods that routine prepares sublimed preparation.
Embodiment 2
Press the row weight portion and take by weighing each medical material: 30 parts in the Radix Rehmanniae, 25 parts of Radix Paeoniae Rubra, 25 parts of Cortex Moutans, 25 parts of Radix Achyranthis Bidentataes, 30 parts of Herba Taraxacis, 30 parts of Herba Violaes, 40 parts of Radix Salviae Miltiorrhizaes, 25 parts of pollen, 25 parts of Radix Angelicae Sinensis, 25 parts of the Radix Paeoniae Albas, 25 parts of Fructus Forsythiaes, 25 parts of Radix Scutellariae, 15 parts in Radix Glycyrrhizae, 12 parts of Radix Dipsaci, 16 parts of Radix Scrophulariae, 15 parts of Cortex Lycii, 15 parts of Radix Sophorae Flavescentiss, 20 parts of Cornu Saigae Tataricae, 20 parts in Herba Spirodelae, 20 parts of Rhizoma Alismatis.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made packed powder according to the pharmaceutical methods that routine prepares powder.
Embodiment 3
Press the row weight portion and take by weighing each medical material: 22 parts in the Radix Rehmanniae, 18 parts of Radix Paeoniae Rubra, 18 parts of Cortex Moutans, 18 parts of pollen, 18 parts of Radix Angelicae Sinensis, 18 parts of the Radix Paeoniae Albas, 18 parts of Fructus Forsythiaes, 18 parts of Radix Scutellariae, 11 parts in Radix Glycyrrhizae, 9 parts of Radix Dipsaci, 10 parts of Radix Scrophulariae, 11 parts of Cortex Lycii, 11 parts of Radix Sophorae Flavescentiss, 12 parts of Cornu Saigae Tataricae, 12 parts in Herba Spirodelae, 12 parts of Rhizoma Alismatis.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made capsule according to the pharmaceutical methods that routine prepares capsule.
Embodiment 4
Press the row weight portion and take by weighing each medical material: 28 parts in the Radix Rehmanniae, 22 parts of Radix Paeoniae Rubra, 22 parts of Cortex Moutans, 22 parts of Radix Achyranthis Bidentataes, 28 parts of Herba Taraxacis, 28 parts of Herba Violaes, 38 parts of Radix Salviae Miltiorrhizaes, 22 parts of pollen, 22 parts of Radix Angelicae Sinensis, 22 parts of the Radix Paeoniae Albas, 22 parts of Fructus Forsythiaes, 22 parts of Radix Scutellariae, 14 parts in Radix Glycyrrhizae, 11 parts of Radix Dipsaci, 15 parts of Radix Scrophulariae, 14 parts of Cortex Lycii, 14 parts of Radix Sophorae Flavescentiss, 18 parts of Cornu Saigae Tataricae, 18 parts in Herba Spirodelae, 18 parts of Rhizoma Alismatis.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made tablet according to the pharmaceutical methods that routine prepares tablet, (as conventional tablet, sugar coated tablet, film coated tablet etc.), and give conventional drug excipient (as starch, sucrose, lactose, calcium stearate, magnesium stearate etc.).
Embodiment 5
Press the row weight portion and take by weighing each medical material: 25 parts in the Radix Rehmanniae, 20 parts of Radix Paeoniae Rubra, 20 parts of Cortex Moutans, 20 parts of Radix Achyranthis Bidentataes, 25 parts of Herba Taraxacis, 25 parts of Herba Violaes, 35 parts of Radix Salviae Miltiorrhizaes, 20 parts of pollen, 20 parts of Radix Angelicae Sinensis, 20 parts of the Radix Paeoniae Albas, 20 parts of Fructus Forsythiaes, 20 parts of Radix Scutellariae, 12 parts in Radix Glycyrrhizae, 10 parts of Radix Dipsaci, 12 parts of Radix Scrophulariae, 12 parts of Cortex Lycii, 12 parts of Radix Sophorae Flavescentiss, 15 parts of Cornu Saigae Tataricae, 15 parts in Herba Spirodelae, 15 parts of Rhizoma Alismatis.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made pill according to the pharmaceutical methods that routine prepares pill, and give conventional drug excipient.
Embodiment 6
Press the row weight portion and take by weighing each medical material: 23 parts in the Radix Rehmanniae, 19 parts of Radix Paeoniae Rubra, 19 parts of Cortex Moutans, 19 parts of Radix Achyranthis Bidentataes, 23 parts of Herba Taraxacis, 23 parts of Herba Violaes, 33 parts of Radix Salviae Miltiorrhizaes, 18 parts of pollen, 18 parts of Radix Angelicae Sinensis, 19 parts of the Radix Paeoniae Albas, 19 parts of Fructus Forsythiaes, 19 parts of Radix Scutellariae, 12 parts in Radix Glycyrrhizae, 10 parts of Radix Dipsaci, 12 parts of Radix Scrophulariae, 12 parts of Cortex Lycii, 12 parts of Radix Sophorae Flavescentiss, 15 parts of Cornu Saigae Tataricae, 15 parts in Herba Spirodelae, 15 parts of Rhizoma Alismatis.
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made granule according to the pharmaceutical methods that routine prepares granule.
Claims (5)
1. a Chinese patent medicine for the treatment of discoid lupus erythematosus is characterized in that being prepared from by following medicaments in part by weight: Radix Rehmanniae 20-30 part, Radix Paeoniae Rubra 15-25 part, Cortex Moutan 15-25 part, Radix Achyranthis Bidentatae 15-25 part, Herba Taraxaci 20-30 part, Herba Violae 20-30 part, Radix Salviae Miltiorrhizae 30-40 part, pollen 15-25 part, Radix Angelicae Sinensis 15-25 part, Radix Paeoniae Alba 15-25 part, Fructus Forsythiae 15-25 part, Radix Scutellariae 15-25 part, Radix Glycyrrhizae 10-15 part, Radix Dipsaci 8-12 part, Radix Scrophulariae 9-16 part, Cortex Lycii 10-15 part, Radix Sophorae Flavescentis 10-15 part, Cornu Saigae Tataricae 10-20 part, Herba Spirodelae 10-20 part, Rhizoma Alismatis 10-20 part.
2. the Chinese patent medicine of treatment discoid lupus erythematosus according to claim 1 is characterized in that being prepared from by following medicaments in part by weight: Radix Rehmanniae 22-28 part, Radix Paeoniae Rubra 18-22 part, Cortex Moutan 18-22 part, Radix Achyranthis Bidentatae 18-22 part, Herba Taraxaci 22-28 part, Herba Violae 22-28 part, Radix Salviae Miltiorrhizae 32-38 part, pollen 18-22 part, Radix Angelicae Sinensis 18-22 part, Radix Paeoniae Alba 18-22 part, Fructus Forsythiae 18-22 part, Radix Scutellariae 18-22 part, Radix Glycyrrhizae 11-14 part, Radix Dipsaci 9-11 part, Radix Scrophulariae 10-15 part, Cortex Lycii 11-14 part, Radix Sophorae Flavescentis 11-14 part, Cornu Saigae Tataricae 12-18 part, Herba Spirodelae 12-18 part, Rhizoma Alismatis 12-18 part.
3. the Chinese patent medicine of treatment discoid lupus erythematosus according to claim 1 is characterized in that being prepared from by following medicaments in part by weight: 25 parts in the Radix Rehmanniae, 20 parts of Radix Paeoniae Rubra, 20 parts of Cortex Moutans, 20 parts of Radix Achyranthis Bidentataes, 25 parts of Herba Taraxacis, 25 parts of Herba Violaes, 35 parts of Radix Salviae Miltiorrhizaes, 20 parts of pollen, 20 parts of Radix Angelicae Sinensis, 20 parts of the Radix Paeoniae Albas, 20 parts of Fructus Forsythiaes, 20 parts of Radix Scutellariae, 12 parts in Radix Glycyrrhizae, 10 parts of Radix Dipsaci, 12 parts of Radix Scrophulariae, 12 parts of Cortex Lycii, 12 parts of Radix Sophorae Flavescentiss, 15 parts of Cornu Saigae Tataricae, 15 parts in Herba Spirodelae, 15 parts of Rhizoma Alismatis.
4. according to the sclerodermatous Chinese patent medicine of the described treatment of arbitrary claim in the claim 1 to 3, it is characterized in that described Chinese patent medicine makes pill, sublimed preparation, powder, tablet, unguentum, decoction and the different oral medicine dosage form of capsule dress powder according to the conventional technology of preparing of Chinese medicine.
5. the sclerodermatous Chinese patent medicine of treatment according to claim 4 is characterized in that described Chinese patent medicine also contains drug excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110156523A CN102228576B (en) | 2011-05-31 | 2011-05-31 | Chinese patent medicine for treating discoid lupus erythematosus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110156523A CN102228576B (en) | 2011-05-31 | 2011-05-31 | Chinese patent medicine for treating discoid lupus erythematosus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102228576A true CN102228576A (en) | 2011-11-02 |
| CN102228576B CN102228576B (en) | 2012-09-12 |
Family
ID=44841208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110156523A Expired - Fee Related CN102228576B (en) | 2011-05-31 | 2011-05-31 | Chinese patent medicine for treating discoid lupus erythematosus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102228576B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599261A (en) * | 2013-11-28 | 2014-02-26 | 谢宗祥 | Traditional Chinese medicine for treating lupus erythematosus |
| CN103721007A (en) * | 2014-01-15 | 2014-04-16 | 李茂林 | Traditional Chinese medicament for treating neonatal erythema toxicum and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810800A (en) * | 2010-05-26 | 2010-08-25 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating skin itch and preparation method thereof |
-
2011
- 2011-05-31 CN CN201110156523A patent/CN102228576B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810800A (en) * | 2010-05-26 | 2010-08-25 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating skin itch and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 韩百灵: "消毒灵", 《中医杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599261A (en) * | 2013-11-28 | 2014-02-26 | 谢宗祥 | Traditional Chinese medicine for treating lupus erythematosus |
| CN103721007A (en) * | 2014-01-15 | 2014-04-16 | 李茂林 | Traditional Chinese medicament for treating neonatal erythema toxicum and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102228576B (en) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102342992B (en) | Chinese medicinal composition for treating insomnia and preparation method of preparation thereof | |
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN102366541B (en) | Traditional Chinese medicine composition for treatment of diabetes | |
| CN104208554A (en) | Traditional Chinese medicine mainly for treating multiple female diseases | |
| CN102058784A (en) | Medicinal composition for treating pulmonary heart disease and application thereof | |
| CN104189783A (en) | Traditional Chinese medicine for treating oral ulcer | |
| CN102362919A (en) | Traditional Chinese medicine for treating scleroderma | |
| CN103285206B (en) | Traditional Chinese medicinal liquor for treating rheumatic arthritis | |
| CN102362934A (en) | Chinese patent medicine for treating erythema nodosum | |
| CN102228576B (en) | Chinese patent medicine for treating discoid lupus erythematosus | |
| CN102430013A (en) | Chinese medicine for treating vitiligo | |
| CN104971331A (en) | Orally-taken externally-applied traditional Chinese medicine composition for treating proliferation of mammary gland and preparation method | |
| CN104784538A (en) | Chinese medicinal preparation for treating diabetes and preparation method | |
| CN107213360A (en) | A kind of Chinese medicine composition for treating heavy myasthenia | |
| CN102362957B (en) | Chinese prepared medicine for treating deep lupus erythematosus | |
| CN103948694A (en) | Wind expelling and arthromyodynia dredging traditional Chinese medicine and preparation method thereof | |
| CN102228619B (en) | Chinese patent medicine for treating systemic lupus erythematosus | |
| CN103845547A (en) | Traditional Chinese medicine decoction for treating mumps | |
| CN102743682B (en) | Chinese medicinal pill for preventing miscarriage of pregnant woman | |
| CN101716307A (en) | Traditional Chinese medicine for treating AIDS | |
| CN102228613B (en) | Chinese patent medicine for treating tinea capitis | |
| CN102552824B (en) | Traditional Chinese medicine prepared prescription for treating psoriasis | |
| CN101095922A (en) | Chinese traditional medicine composition for treating diabetes peripheral neuritis | |
| CN104840856A (en) | Traditional Chinese medicine prescription for treating anemia | |
| CN105943924A (en) | Traditional Chinese medicine for treating gallbladder fire exuberance syndrome type multiple gall-stone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: WANG LIANFEN Effective date: 20131128 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 264000 YANTAI, SHANDONG PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131128 Address after: 226400, friendship road, Nantong Town, Rudong County, Jiangsu, 66 Patentee after: Rudong science and Technology Center Address before: 264000 Yantai psoriasis research institute, 11 Wenhua Road, Zhifu District, Shandong, Yantai Patentee before: Wang Lianfen |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200703 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400, friendship road, Nantong Town, Rudong County, Jiangsu, 66 Patentee before: Rudong science and Technology Center |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200904 Address after: 102200 Room 204, floor 104, floor 1-4, building 2, Tiantong Xiyuan District 3, Dongxiaokou Town, Changping District, Beijing Patentee after: Beijing Gulou Research Institute of difficult diseases Co.,Ltd. Address before: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong industrial and commercial information consulting service center |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120912 |